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Background: Corticotropin-releasing factor (CRF) plays an important role in affective states and disorders. CRF is
not only a “stress hormone” but also a neuromodulator outside the hypothalamic-pituitary-adrenocortical (HPA)
axis. The amygdala, a brain center for emotions, is a major site of extrahypothalamic expression of CRF and its
G-protein-coupled receptors. Our previous studies showed that endogenous activation of CRF1 receptors in an
arthritis pain model contributes to amygdala hyperactivity and pain-related behaviors. Here we examined the
synaptic and behavioral effects of CRF in the amygdala of normal animals in the absence of tissue injury or disease.
Results: Whole-cell patch-clamp recordings of neurons in the latero-capsular division of the central nucleus of the
amygdala (CeLC) in brain slices from normal rats showed that CRF (0.1-10 nM) increased excitatory postsynaptic
currents (EPSCs) at the “nociceptive” parabrachio-amygdaloid (PB-CeLC) synapse and also increased neuronal output.
Synaptic facilitation involved a postsynaptic action and was blocked by an antagonist for CRF1 (NBI27914, 1 μM) but
not CRF2 (astressin-2B, 1 μM) and by an inhibitor of PKA (KT5720, 1 μM) but not PKC (GF109203X, 1 μM). CRF increased
a latent NMDA receptor-mediated EPSC, and this effect also required CRF1 and PKA but not CRF2 and PKC. Stereotaxic
administration of CRF (10 μM, concentration in microdialysis probe) into the CeLC by microdialysis in awake rats
increased audible and ultrasonic vocalizations and decreased hindlimb withdrawal thresholds. Behavioral effects of CRF
were blocked by a NBI27914 (100 μM) and KT5720 (100 μM) but not GF109203x (100 μM). CRF effects persisted when
HPA axis function was suppressed by pretreatment with dexamethasone (50 μg/kg, subcutaneously).
Conclusions: Non-pain-related activation of CRF1 receptors in the amygdala can trigger pain-responses in normal
animals through a mechanism that involves PKA-dependent synaptic facilitation in CeLC neurons independent of HPA
axis function. The results suggest that conditions of increased amygdala CRF levels can contribute to pain in the
absence of tissue pathology or disease state.
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Corticotropin releasing factor (CRF) plays an important
role in emotional processes and neuropsychiatric disorders
such as anxiety, depression and addiction [1-5]. CRF acts
on CRF1 and CRF2 receptors that can couple to multiple
G proteins to activate a number of intracellular effectors
such as protein kinase A and C (PKA and PKC) [6-9].
Antagonists selective for CRF1 have been developed for
clinical trials. Whereas an open-label trial study reported* Correspondence: voneugeb@utmb.edu
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reproduction in any medium, provided the oreffectiveness in human patients with major depressive
disorder [10], evidence from several clinical trials now
suggests that CRF1 antagonists may be more useful in
certain anxiety disorders such as posttraumatic stress
disorder (PTSD) and in addiction disorders [5].
The amygdala, a major site of extra-hypothalamic expres-
sion of CRF and its receptors, has emerged as a key element
of the circuitry through which CRF acts as a neuromodulator
outside the hypothalamic-pituitary-adrenocortical (HPA) axis
to mediate behavioral responses to stressors [1,2,4,8,9,11-15].
CRF-containing neurons are found in the central nucleus
of the amygdala (CeA), which serves as the output nucleus
for major amygdala functions [16-18]. CRF neurons in thehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and brain stem [12] and in turn receive input from calci-
tonin gene-related peptide (CGRP) terminals [19] arising
from brainstem neurons in the lateral parabrachial area
[20]. The latero-capsular division of the central nucleus
(CeLC) is delineated by these CGRP containing fibers
from the parabrachial area (PB) that provide unfiltered
nociceptive information to the CeLC as part of the spino-
parabrachio-amygdaloid pain pathway [21,22]. Pain-related
plasticity at the PB-CeLC synapse has been shown in dif-
ferent pain models [23-30]. CeLC plasticity drives pain-
related emotional-affective responses and anxiety-like
behavior [21,22].
Accumulating evidence from biochemical [31-33], behav-
ioral [29,34-36] and electrophysiological studies [29,37,38]
suggests that CRF in the amygdala, particularly in the CeA,
plays an important role in pain modulation and pain-
related affect. These studies showed increased CRF mRNA
expression in the CeA in models of visceral [31] and neuro-
pathic [32,33] pain. Inhibition of CRF-binding protein in
the CeA to increase availability of CRF increased mechan-
ical sensitivity in neuropathic animals and this effect was
blocked by a non-selective CRF receptor antagonist [36].
Microinjections of a non-selective CRF receptor antagonist
into the CeA reduced hyperalgesia (tail flick test) associated
with morphine withdrawal without affecting plasma cor-
ticosterone responses [34]. Blockade of CRF1 receptors in
the CeA inhibited pain- and anxiety-like behaviors in a
model of arthritic pain [29,35] whereas a non-selective CRF
receptor antagonist had no effect in a neuropathic pain
model [36]. A CRF1 receptor antagonist inhibited pain-
related central sensitization and attenuated synaptic plasti-
city in CeA neurons [29,37].
Little is known about the effects of CRF administra-
tion to the amygdala (CeA) on pain-related behavior
and underlying neuronal mechanisms under normal
conditions in the absence of disease or injury. Our pre-
vious studies suggest that the CRF system is not active
under normal conditions because CRF receptor antagonists
had no effect on their own [29,37]. Intra-CeA application
of CRF increased responsiveness of CeLC neurons in
normal animals but also had inhibitory effects at higher
concentrations [38]. It is not clear if these effects were
due to direct actions on CeLC neurons or in the amyg-
dala network. In brain slices, CRF inhibited the slow
afterhyperpolarization following evoked action potential
firing, which would increase excitability [39].
Here we determined the synaptic effects of CRF on CeLC
neurons, contribution of CRF1 and CRF2 receptors, signal-
ing mechanisms and behavioral consequences under nor-
mal conditions. The significance of this study is that the
amygdala CRF system is not only engaged in conditions of
pain and anxiety disorders but can by itself trigger pain in
the absence of any injury or disease.Results
Neurons in the latero-capsular division of the CeA (CeLC)
with non-accommodating spike firing properties were
recorded in brain slices from untreated normal rats. These
are Type A projection neurons that target brainstem and
forebrain areas [21,40,41] Neurons were selected that
showed an excitatory synaptic response to electrical stimu-
lation of presumed parabrachial (PB) afferents (PB-CeLC
synapse; see Methods) as described in our previous studies
[25,29]. These CeLC neurons form the “nociceptive
amygdala” [21,22]. They develop CRF1 receptor-dependent
central sensitization and synaptic plasticity in an arthritis
pain model [29,37], but synaptic and behavioral effects of
non-pain-related CRF increases in the CeLC under normal
conditions remain to be determined.
Since characteristics of CeLC neurons with PB input
have been described in detail in our previous studies
[22] for recent references see [30,42,43] this report will
focus on the novel findings related to the exogenous ap-
plication of CRF to the amygdala. The first part of this
study examined CRF effects on synaptic transmission
and the involvement of CRF1 versus CRF2 receptors and
PKA versus PKC in brain slices from normal animals.
Only one or two brain slices per animal were used; one
neuron was recorded in each slice, and a fresh slice was
used for each new experimental protocol. Numbers in
the manuscript refer to the number of neurons tested
for each parameter. The second part of this study takes
these findings to behavioral level, measuring pain-like
responses (vocalizations and reflexes) in awake animals.
Facilitation of synaptic transmission by CRF through CRF1
receptors
Superfusion of the brain slice with CRF (0.1-10 nM)
increased excitatory transmission at the PB-CeLC synapse
concentration-dependently in 7 of 10 neurons (P < 0.001,
one-way ANOVA; Figure 1A). Monosynaptic excitatory
postsynaptic currents (EPSCs) were evoked by electrical
stimulation of presumed PB afferents [25,28,29]. Baseline
EPSCs at the PB-CeLC synapse recorded at resting
membrane potential are mediated by non-NMDA receptors
since they persist in the presence of NMDA receptor
blockade as shown in our previous studies [28] and
confirmed by others [24]. CRF enhanced the input–output
function of the PB-CeLC synapse significantly (Figure 1D,E,
n = 7 neurons in each sample; P < 0.0001, F1,60 = 12.94
and 19.02, respectively; two-way ANOVA). Input–output
relationships were obtained by increasing stimulus inten-
sities to measure EPSC peak amplitude as a function of
afferent fiber volley stimulus intensity for each neuron.
Synaptic facilitation by CRF (10 nM) was blocked by co-
administration of a CRF1 receptor antagonist (NBI27914,
1 μM, n = 5 neurons; P < 0.01, Bonferroni posttest;
Figure 1B,D) but not by a CRF2 receptor antagonist
Figure 1 CRF enhances synaptic transmission in the CeLC in slices from normal animals. (A) Concentration-response relationship of CRF
effects on monosynaptic EPSCs (numbers of neurons tested with each concentration are indicated). Peak amplitudes were averaged for each
concentration of CRF and expressed as percent of predrug control (set to 100%). Concentration-response curve was obtained by non-linear
regression analysis using the formula y = A + (B − A)/[1 + (10C/10X)D], where A is the bottom plateau, B top plateau, C = log(EC50), and D is the
slope coefficient (GraphPad Prism software). *** P < 0.001, Bonferroni posttests compared to predrug. (B-E) Synaptic facilitation by CRF (10 nM,
12 min) was blocked by co-administration of an antagonist for CRF1 (NBI27914, NBI; 1 μM, 12 min) but not for CRF2 (astressin-2B, AStr2B; 1 μM,
12 min). (B, C) Monosynaptic EPSCs recorded in ACSF (Predrug), during CRF, and during CRF together with NBI27914 (B) or astressin-2B (C). Individual
traces are the average of 8–10 EPSCs. (D) CRF increased input–output function significantly (n = 7 neurons). NBI27914 (n = 5) decreased the
effect of CRF. Input–output curves were generated by plotting peak EPSC amplitude (pA) as a function of afferent fiber volley stimulus intensity
(μA). (E) Astressin-2B (n = 5) had no significant (ns) effect on CRF-induced synaptic facilitation (n = 7). *,**,*** P < 0.05, 0.01, 0.001, Bonferroni
posttests compared to predrug. ## P < 0.01, Bonferroni posttests compared to CRF. CeLC neurons were recorded at −60 mV in slices from naïve
untreated animals. Symbols and error bars represent means ± SEM.
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posttest; Figure 1C,E). These data show the presence of
functional CRF1 receptors in the CeLC under normal
conditions and the ability of CRF to facilitate excitatory
synaptic transmission.
CRF acts postsynaptically to increase synaptic
transmission
To determine the synaptic site of action of CRF in the CeLC
we analyzed amplitude and frequency distribution of mini-
ature EPSC (mEPSC) in the presence of TTX, which is a
well-established electrophysiological method to distinguish
pre- and postsynaptic mechanisms [44]. Presynaptic effects
at the transmitter release site change mEPSC frequency
whereas postsynaptic membrane effects alter mEPSC ampli-
tude (quantal size). CRF (10 nM, 12 min) increased ampli-
tude (Figure 2B) but not frequency (Figure 2C) of mEPSCsin the presence of TTX (1 μM), causing a significant shift
of the cumulative mEPSC amplitude distribution towards
larger amplitudes (P < 0.0001, Kolmogorov-Smirnov test;
Figure 2B) and increasing the mean mEPSC amplitude in
the sample of neurons significantly (n = 5, P < 0.05, paired
t-test; Figure 2B, bar histogram). CRF had no significant
effect on the frequency of mEPSCs (see cumulative inter-
event interval distribution, P > 0.05, Kolmogorov-Smirnov
test; mean frequency for the sample of neurons, n = 5, P >
0.05, paired t-test; Figure 2C). The results are consistent
with a postsynaptic site of action of CRF.
CRF increases CeLC output (depolarization-induced spiking)
Action potentials were evoked under current-clamp mode
by direct intracellular current injections of increasing
magnitude through the patch electrode (Figure 3). Input–
output functions of neuronal excitability (frequency-
Figure 2 Post- rather than pre-synaptic effect of CRF. (A) Original
current traces of miniature EPSCs (mEPSCs) recorded in the
presence of TTX (1 μM) in one CeLC neuron before (Predrug) and
during CRF (10 nM). Scale bars, 20 pA, 200 ms. CRF (10 nM, 12 min)
increased amplitude (B) but not frequency (C) of mEPSC
significantly (cumulative inter-event interval distribution for
individual neuron, P < 0.0001, Kolmogorov–Smirnov test; mean
frequency, n = 5 neurons, P < 0.05, paired t-test). Data for each
neuron were obtained from 2 predrug recording periods and 2
recording periods during CRF (5 min each period). Bar histograms
show means ± SEM expressed as percent of predrug control (set to
100%). Statistical analysis was done using raw data.
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the frequency of action potentials evoked at each current
intensity. CeLC neurons were regular-spiking and showed
no accommodation of action potential firing in response
to sustained depolarization, which are characteristics of
Type A projection neurons [40,41]. CRF (10 nM, 12 min)
significantly increased the input–output function of CeLC
neurons (Figure 3A,B, n = 5 neurons in each sample;
P < 0.0001, F1,56 = 14.87 and 15.68, respectively, two-way
ANOVA). A CRF1 receptor antagonist (NBI27914, 1 μM,
12 min, n = 5) blocked the effect of CRF (P < 0.0001, F1,56 =
14.53, two-way ANOVA; Figure 3A). In contrast, a CRF2
receptor antagonist (astressin-2B, 1 μM, n = 5) had no sig-
nificant effect (P > 0.05, F1,56 = 0.89, two-way ANOVA)
hence the excitatory action of CRF continued. The persist-
ence of CRF effects in the presence of the CRF2 antagonist
argues against the loss of effectiveness of prolonged CRF
application (30 min), e.g., through desensitization, as an
explanation for the inhibitory effect of the CRF1 antag-
onist. Thus, CRF increases CeLC output through CRF1
receptor activation.
Inhibition of PKA, but not PKC, blocks CRF-induced
synaptic facilitation
CRF receptors can couple to a number of signaling pathways
including cAMP-PKA activation (see Background). PKA,
but not PKC, plays a critical role in pain-related plasti-
city in the CeLC [45]. Therefore, we tested the hypoth-
esis that CRF-induced synaptic facilitation depends on
PKA. Co-application of a selective PKA inhibitor (KT5720,
1 μM) decreased synaptic facilitation by CRF significantly
(Figure 4A, B, n = 5, P < 0.01, compared to the data point
immediately before KT5720 application, Bonferroni
posttests). The effect of KT5720 was reversible. Prolonged
application of CRF alone (10 nM) resulted in continued
synaptic facilitation (Figure 4C, n = 6, P < 0.001, compared
to predrug, Bonferroni posttests). In contrast, a select-
ive PKC inhibitor (GF109203x, 1 μM) had no significant
effect on CRF-induced synaptic facilitation (Figure 4D, E,
n = 5, P > 0.05, Dunnett's multiple comparison test). The
data show an important contribution of PKA to CRF1
receptor-mediated synaptic facilitation.
Figure 3 CRF increases depolarization-induced spiking. Whole-cell current-clamp recordings of action potentials generated by intracellular
(through the patch electrode) injections of depolarizing current pulses (500 ms) of increasing magnitude (in 50 pA steps) from a membrane
potential of −60 mV. (A, B) Upper traces show action potential firing rate increased during superfusion of CRF (10 nM, 12 min). Lower traces
show depolarizing current steps. Graphs show input–output functions (frequency-current [F-I] relationships) averaged for each sample of neurons.
CRF increased F-I relationships significantly (A, n = 5 neurons; P < 0.0001, F1,56 = 14.87; B, n = 5 neurons; P < 0.0001, F1,56 = 15.68; compared to
predrug, two-way ANOVA). (A) A CRF1 receptor antagonist (NBI27914, NBI, 1 μM, n = 5) blocked the effect of CRF significantly (P < 0.0001, F1,56 = 14.53,
two-way ANOVA). (B) A CRF2 receptor antagonist (astressin-2B, AStr2B, 1 μM, n = 5) had no significant effect (P > 0.05, F1,56 = 0.89, compared to CRF,
two-way ANOVA). Symbols and error bars represent means ± SEM.
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through CRF1 and PKA
PKA activation can increase NMDA receptor function
in CeLC neurons, which plays an important role in syn-
aptic plasticity associated with arthritis pain [28] but
not neuropathic pain [24]. In addition, the facilitatory
effect of another neuropeptide, calcitonin gene-related
peptide (CGRP), on CeLC neurons depends on PKA-
mediated activation of NMDA receptors [27,46]. There-
fore, we examined the effect of CRF on NMDA receptor-
mediated transmission at the presumed PB-CeLC synapse
(Figure 5). CRF (10 nM) increased a small latent NMDA
receptor-mediated synaptic response that was unmasked
at a depolarized holding potential (+20 mV) in the pres-
ence of NBQX (20 μM) and bicuculline (30 μM) and
was completely blocked by an NMDA receptor antagon-
ist (AP5, 50 μM; not shown). An antagonist for CRF1
(NBI27914, 1 μM, n = 5, Figure 5A) but not CRF2
(astressin-2B, 1 μM, n = 5, Figure 5B) receptors inhibited
the facilitation by CRF significantly (P < 0.01, Bonferroni
posttest). An inhibitor of PKA (KT5720, 1 μM, n = 5,
Figure 5C), but not PKC (GF109203x, 1 μM, n = 5,
Figure 5D), blocked the CRF-induced facilitation of the
NMDA EPSC significantly (P < 0.01, Bonferroni posttest).
The data suggest that CRF can engage NMDA receptor-
mediated synaptic transmission through a mechanism
that involves CRF1 and PKA activation. It should benoted that our previous studies showed that CRF recep-
tor antagonists and PKA and PKC inhibitors have no
effect on their own under normal conditions [29,45].
These control experiments were not repeated here.
CRF increases vocalizations and spinal reflexes through
CRF1 receptors
Changes in PB-CeLC transmission and activity of CeLC
neurons are positively correlated with pain-like behaviors
[21,22]. Therefore we examined the behavioral consequences
of CRF-induced facilitation of synaptic transmission. The
effects of CRF administered into the CeLC on spinally
(hindlimb withdrawal reflexes) and supraspinally (vocal-
izations) organized behaviors were measured in normal
naïve animals. Thresholds for hindlimb withdrawal reflexes
were determined by compressing the knee joint with grad-
ually increasing stimulus intensities using a calibrated for-
ceps whose output was displayed on an LCD screen (see
Methods). Vocalizations in the audible (20 Hz to 16 kHz)
and ultrasonic (25 ± 4 kHz) ranges reflect nocifensive and
affective responses, respectively, to aversive stimuli [47].
Vocalizations evoked by brief (15 s) mechanical stimulation
of the knee were recorded for a period of 1 min starting
with the onset of the stimulus, using a computerized ana-
lysis system (see Methods) as described previously [47,48].
No apparent differences were found in this study for drug
effects on vocalizations during stimulation and vocalization
Figure 4 Inhibition of PKA, but not PKC, blocks CRF-induced
synaptic facilitation. (A) Original recordings of monosynaptic EPSCs
(average of 8–10 traces). Facilitatory effects of CRF (10 nM) were
blocked by co-administration of a PKA inhibitor (KT5720, 1 μM).
(B) Summary of time course data for the sample of CeLC neurons
(n = 5). Peak amplitudes of EPSCs recorded during drug application
were expressed as percent of predrug control values (set to 100%).
Symbols and error bars represent means ± SEM. *,** P < 0.05, 0.01,
compared to predrug before CRF; ## P < 0.01, compared to the
data point immediately before KT5720 application; ANOVA with
Bonferroni posttests. (C) Time course data for prolonged
application of CRF without a PKA inhibitor (n = 6). Display as in
(B). *** P < 0.001, compared to predrug, Dunnett’s multiple
comparison tests. (D) Individual traces (average of 8–10) of
monosynaptic EPSCs show that the facilitatory effect of CRF (10 nM)
was not blocked by co-administration of a PKC inhibitor (GF109203x,
1 μM). (E) Time course data for GF109203x effects (n = 5). Significant
facilitation by CRF persisted during coapplication of GF109203x. Display
as in (B). *** P < 0.001, compared to predrug, Dunnett’s multiple
comparison tests. Statistical analysis was performed on raw data.
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individual vocalization events) for the recording period is
shown. Rats did not vocalize spontaneously in a control
period of 5–10 min before stimulation.
Administration of CRF (1 μM, concentration in the
microdialysis probe; 30 min) into the CeLC increased the
duration of audible (Figure 6A) and ultrasonic (Figure 6B)
vocalizations significantly (n = 6 in each group, P < 0.01-
0.001 compared to predrug controls, Bonferroni posttests).
CRF also decreased the threshold for hindlimb withdrawal
reflexes significantly (n = 5, P < 0.01; Figure 6C). Predrug
baseline measurements were made during administration
of ACSF through the microdialysis probe as vehicle
control. There was no difference between behavioral
responses measured at 15 min and 30 min during continued
CRF administration. This allowed us in subsequent
experiments to coapply blockers with CRF starting
15 min after the onset of CRF administration. Coapplication
of a CRF1 receptor antagonist (NBI27914, 100 μM, 15 min)
into the CeLC decreased audible and ultrasonic vocal-
izations (n = 6) and spinal reflexes (n = 5) significantly (P <
0.05-0.001, compared to CRF alone at 15 min, Bonferroni
posttests; Figure 6D-F). We did not test a CRF2 receptor
antagonist because the electrophysiological effects of
CRF on CeLC neurons in brain slices did not involve
CRF2 receptors.
Behavioral effects of CRF depend on PKA but not PKC
Co-administration of a PKA inhibitor (KT5720, 100 μM,
concentration in microdialysis probe) disrupted the facili-
tatory effects of CRF (1 μM) on audible (Figure 7A) and
ultrasonic (7B) vocalizations significantly (n = 5, P < 0.05-
0.01, compared to CRF alone at 15 min, Bonferroni
posttests). KT5720 also inhibited the effects of CRF on
withdrawal thresholds (Figure 7C, n = 5, P < 0.001,
Figure 5 CRF increases NMDA receptor-mediated transmission
through CRF1 and PKA. (A-D) CRF (10 nM) increased a small
pharmacologically (bicuculline, 30 μM; NBQX, 20 μM) isolated NMDA
component recorded at a holding potential of +20 mV that was
blocked by an NMDA receptor antagonist (AP5, 50 μM; not shown).
Bar histograms show averaged data (mean ± SE). Individual traces
are the average of 8–10 EPSCs recorded at +20 mV. (A) A CRF1
receptor antagonist (NBI27914, 1 μM, n = 5) inhibited the facilitatory
effect of CRF. (B) A CRF2 receptor antagonist (astressin-2B, AStr2B,
1 μM, n = 5) had no effect. (C) A PKA inhibitor (KT5720, 1 μM, n = 5)
blocked the CRF-induced facilitation. (D) A PKC inhibitor (GF109203x,
1 μM, n = 5) had no effect. Drugs were applied for 12–15 min.
** P < 0.01; ns (not significant) P > 0.05; ANOVA with Bonferroni
posttests. Statistical analysis was performed on raw data.
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In contrast, co-administration of a PKC inhibitor
(GF109203x, 100 μM) had no significant effect on CRF-
enhanced vocalizations (Figure 7D, E, n = 6) and spinal
reflexes (Figure 7F, n = 5). We showed previously that
inhibitors of PKA and PKC alone have no effect on
vocalizations and spinal reflexes in normal animals [45].
These control experiments were not repeated here.
Behavioral effects of CRF are independent of HPA axis
function
CRF can act as a neuromodulator through extrahypo-
thalamic mechanisms independently of HPA axis functions
[1-4,8,11,13,49]. To determine if this is the case in
amygdala-mediated pain modulation we used a well-
established experimental approach, the so-called dexa-
methasone (Dex) suppression test (DST), in which
pretreatment with a low dose of Dex (0.05 mg/kg,
subcutaneously) suppresses the pituitary-adrenal response
to CRF and inhibits plasma corticosterone increase [50,51].
Using this protocol we pretreated rats with dexamethasone
(0.05 mg/kg, subcutaneously) 2 hours prior to CRF admin-
istration into the CeLC. Injection of Dex had no significant
effect on audible and ultrasonic vocalizations and spinal
reflex thresholds measured 15 min before CRF adminis-
tration (n = 6 rats; Figure 8A-C). Pretreatment with Dex
did not block the facilitatory effects of CRF (1 μM, con-
centration in the microdialysis probe; 15 min) that were
statistically significant (P < 0.05-0.001, compared to Dex
alone, Bonferroni posttests, n = 5 rats; Figure 8A-C).
The data suggest that HPA axis function is not required
for amygdala CRF to modulate pain-like behaviors.
Placement controls and histology
As a control for drug diffusion, CRF (1 μM, concentra-
tion in the microdialysis probe; 30 min) was administered
into the adjacent striatum as in our previous studies
[43,45,46,48]. CRF in the striatum had no significant effect
on vocalizations and spinal reflexes (n = 6 rats; Figure 8D-F).
Drug application sites into the CeLC and striatum were
Figure 6 A CRF1 receptor antagonist reverses CRF-induced increases of audible vocalizations and spinal reflexes. Administration of CRF
(1 μM, concentration in microdialysis fiber) into the CeLC increased the duration of audible (A) and ultrasonic (B) vocalizations (voc.) evoked by
innocuous (500 g/30 mm2) and noxious (2000 g/30 mm2) stimulation of the knee (n = 6 rats). (C) CRF decreased reflex thresholds for mechanical
stimulation of the knee (n = 5 rats). Behaviors were measured at 15 and 30 min of CRF administration. The effects of CRF persisted during
continued administration. (D,E) Coapplication of a CRF1 receptor antagonist (NBI27914, 100 μM, concentration in microdialysis probe, 15 min)
with CRF decreased CRF-enhanced audible and ultrasonic vocalizations significantly (n = 6 rats). (F) NBI27914 also inhibited the CRF effect
on spinal reflex thresholds (n = 5 rats). Bar histograms show means ± SEM. *,**,*** P < 0.05-0.001, compared to predrug (ACSF) before CRF;
#,##,### P < 0.05-0.001, compared to CRF (15 min time point); Bonferroni posttests.
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position of the tips of the microdialysis probes for the differ-
ent sets of behavioral experiments (see Figures 6, 7, 8).
Discussion
The novelty of this study is the correlation of electro-
physiological effects of CRF in the amygdala with pain-
like behaviors under normal conditions in the absence of
injury or disease. We show that CRF administered to the
CeLC, a brain area that plays a critical role in the
emotional-affective component of pain [21,22], enhances
or triggers nocifensive and affective behaviors by increas-
ing synaptic transmission and neuronal output through
postsynaptic CRF1 receptor-mediated PKA activation.
CRF facilitated synaptic transmission at the PB-CeLC
synapse that provides unfiltered nociceptive information
from spinal cord and brainstem to the CeLC and under-
goes plasticity in different pain models [23-30]. Increased
transmission at the PB-CeLC synapse correlates with
pain- and anxiety-like behaviors [21,22]. Analysis of mini-
ature EPSCs indicated a post- rather than presynaptic
action of CRF. CRF also increased spike firing, suggesting
increased neuronal output. We did not attempt to deter-
mine the ionic basis for this cellular effect. Our previousstudies using CRF receptor antagonists in the arthritis
pain model implicated Kv3-type potassium channels in
the effects of endogenous activation of CRF1 receptors;
Kv3 channel regulate firing rate through action potential
repolarization [29]. However, a number of other effects
of CRF on electrophysiological properties of amygdala
neurons have been described, including inhibition of
the slow afterhyperpolarizing potential (AHP) following
evoked repetitive firing, mixed effects on the medium
AHP [39], and increase of R-type voltage-gated calcium
channels [52]. Importantly, non-accommodating Type A
neurons recorded in this study only show a medium AHP
whereas the slow AHP is characteristic of accommodating
Type B neurons [40]. Therefore, the mechanisms of any
membrane effects of CRF are likely complex and warrant
the detailed analysis in a separate study.
The effects of CRF could be blocked with a CRF1 but
not CRF2 receptor antagonist, demonstrating the presence
of functional CRF1 receptors in the CeLC under normal
conditions. This is not trivial because CRF1 antagonists
had no effect on their own under normal conditions in
previous studies from our group [29,37] and others [36].
The lack of involvement of CRF2 receptors in CRF-
induced synaptic facilitation may be due to the lower
Figure 7 Inhibition of PKA, but not PKC, blocks CRF effects on audible vocalizations and spinal reflexes. (A,B) Coapplication of a PKA
inhibitor (KT5720, 100 μM, concentration in microdialysis probe, 15 min) decreased the facilitatory effect of CRF on audible and ultrasonic
vocalizations (voc.) significantly (n = 5 rats). (C) KT5720 also inhibited the CRF effect on spinal reflex thresholds (n = 5 rats). (D,E,F) Coapplication of
a PKC inhibitor (GF109203x, 100 μM, concentration in microdialysis probe, 15 min) did not block the effects of CRF on audible and ultrasonic
vocalizations (n = 6 rats) and on spinal reflex thresholds (n = 5 rats). Bar histograms show means ± SEM. *,**,*** P < 0.05-0.001, compared to
predrug (ACSF) before CRF; #,##,### P < 0.05-0.001, compared to CRF (15 min time point); Bonferroni posttests.
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pression levels of CRF1 and CRF2 receptors in the synap-
tic circuit studied here [54,55]. CRF2 receptor mRNA
expression is more restricted than that of CRF1, at least
under normal conditions; highest levels of CRF2 receptor
mRNA in the brain are found within the lateral septum,
ventromedial hypothalamus and choroid plexus, while
medial and posterior cortical nuclei of the amygdala show
moderate expression levels [55,56].
CRF effects were largely blocked by inhibition of PKA
but not PKC. CRF receptors can couple to a number of
G-proteins to activate a variety of intracellular signaling
pathways, and PKA and PKC appear to play particular
important roles [6]. PKA is a critical contributor to pain-
related plasticity of CeLC neurons in the arthritis model
[28,45]. A consequence of PKA activation is the NR1 sub-
unit phosphorylation of NMDA receptors in the CeLC
and increased NMDA receptor-mediated synaptic trans-
mission in the arthritis pain model [27,28]. The present
study found that CRF can increase a latent NMDA com-
ponent through CRF1 receptor-mediated PKA activation,
suggesting that CRF can engage processes similar to those
that generate synaptic plasticity in pain models such as
arthritis.
Interestingly, synaptic plasticity in the CeLC in neuro-
pathic pain does not depend on NMDA receptors [24]although NMDA receptor antagonists are effective in the
CeA in reducing nocifensive and affective pain behaviors
in a neuropathic pain model [57]. CRF and CRF mRNA
are increased in CeA neurons in neuropathic pain [33] but
increasing endogenous CRF in the CeA with a CRF-
binding protein inhibitor had mixed effects in neuropathic
pain, facilitating nocifensive responses while attenuating
emotional-affective behaviors [36]. The data may suggest
that NMDA and CRF receptors engage different elements
of the intra-amygdala circuitry in neuropathic pain, acting
for example on inhibitory systems that modulate CeA
processing [30] and neuropathic pain responses [58] and
can be engaged by CRF1 [59] or CRF2 [29] receptors.
Here we focused on the modulation of excitatory trans-
mission at the PB-CeLC that correlates positively with
pain behaviors [21,22] although this study does not rule
out additional sites of action of CRF in the amygdala net-
work that should be explored.
In our study, the electrophysiological effects of CRF
correlated with behavioral consequences. CRF increased
audible and ultrasonic vocalizations, which represent
supraspinally organized nocifensive and affective responses
to aversive stimuli [47], and decreased thresholds for spinal
reflexes. The results are consistent with the concept that
increased CeLC output, here induced by CRF, facilitates
spinal and supraspinal behaviors. It remains to be
Figure 8 HPA axis function and placement controls. (A-C) To suppress HPA axis function rats were pretreated with dexamethasone (Dex,
0.05 mg/kg, subcutaneously) 2 hours prior to CRF administration into the CeLC [50,51]. Injection of Dex had no significant (ns) effect on audible
and ultrasonic vocalizations and spinal reflex thresholds measured 15 min before CRF administration (n = 6 rats). Administration of CRF (1 μM,
concentration in the microdialysis probe; 15 min) into the CeLC following pretreatment with Dex had significant facilitatory effects (n = 5 rats).
(D-F) Administration of CRF (1 μM, concentration in the microdialysis probe; 15 min) into the adjacent striatum as a placement control had no
significant effect on vocalizations and reflex thresholds (n = 6). Bar histograms show means ± SEM. *,**,*** P < 0.05-0.001, compared to Dex
alone; ns (not significant) P > 0.05, compared to predrug; Bonferroni posttests.
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facilitation or disinhibition [21]. Non-accommodating
Type A neurons in the CeA project to brainstem and
forebrain areas involved in the expression of aversive
behaviors and pain modulation, including the periaqueductal
gray. These brainstem projections arise not only from
medial but also lateral regions of the CeA and involve
strong interconnections between CeLC and substantia
innominata [21,40,60,61]. Lateral CeA projection neurons
contain a number of neuropeptides, including CRF,
neurotensin and somatostatin, and the latero-capsular re-
gion is the major site of extrahypothalamic CRF expres-
sion [12,33]. Direct brainstem projections from CeA can
be glutamatergic [62] but CRF-containing CeA neurons
also include a population of GABergic neurons [63,64].
Therefore, CeLC output can activate descending facilita-
tion or inhibit descending inhibition (dis-inhibition) to
produce the behavioral effects of CRF observed in our
study. The results of our experiments in which the HPA
axis response was suppressed with dexamethasone pre-
treatment distinguish this neuromodulatory function of
CRF from its role as a stress hormone.
The significance of our findings is that increasing CRF
in the amygdala can trigger pain-like behaviors in nor-
mal animals and these behavioral effects correlate with
increased neuronal activity in the CeLC. Pain arisingfrom altered brain functions in the absence of tissue in-
jury represents a clinically important concept that could
explain pain or increased pain sensitivity in conditions
of anxiety, depression, or addiction such as alcohol de-
pendence [4,9,13,65] that involve the CRF system in the
amygdala. With regard to pain processing and pain
modulation, exogenous application of CRF (this study)
and endogenous release of CRF measured indirectly
with a CRF1 receptor antagonist in our previous studies
[29,37] appear to have similar facilitatory effects.
Some technical aspects of our study deserve consider-
ation. Choice of drugs at appropriate concentrations is
critical for pharmacological validity. We used selective
compounds at concentrations that are well established
in the literature [7,66-68] and in our own previous stud-
ies [29,35,37,38,45]. The fact that a selective CRF1 antag-
onist inhibited the synaptic and behavioral effects of
CRF clearly implicates CRF1 receptors. The lack of effect
of a CRF2 receptor antagonist was not due to an insuffi-
cient drug concentration because the same concentra-
tion produced facilitatory effects in a pain model in our
previous study [29]. Likewise, the PKC inhibitor was used
at a concentration near the high end of the selective range
to ensure the lack of effect on CRF functions was not due
to an insufficient concentration. A lower concentration of
this inhibitor has been shown to be effective in modulating
Figure 9 Histological verification of drug application sites. Diagrams adapted from Paxinos and Watson [75] show coronal sections through
the right hemisphere at different levels posterior to bregma (−1.88 and −2.12). Next to each diagram is shown in detail the medial (CeM), lateral
(CeL) and latero-capsular (CeLC) divisions of the central nucleus of the amygdala. Each symbol indicates the location of the tip of one
microdialysis probe. The boundaries of the different amygdala nuclei are easily identified under the microscope (see Figure 1 in [29]). (A) Drug
application sites for experimental data shown in Figure 6. (B) For data in Figure 7. (C) For data in Figure 8A-C. (D) For data in Figure 8D-F.
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caveats need to be considered for drug application by
microdialysis. While the concentration of the drug in the
microdialysis fiber is known, the drug dose administered
can only be estimated. Comparative data from our previ-
ous microdialysis and in vitro studies using CRF receptor
compounds [29,35,37,70] indicate that the tissue concen-
tration is at least 100 times lower than in the microdialysisprobe due to the concentration gradient across the dialysis
membrane and diffusion in the tissue. Therefore, drugs
were dissolved in ACSF at a concentration 100 times that
predicted to be needed. Microdialysis was chosen for drug
delivery because it offers several advantages, including
continued drug delivery and steady state levels without a
volume effect [71]. Differential effects of CRF1 and CRF2
receptor antagonists and PKA and PKC inhibitors here
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non-selective drug effects at the concentrations used.
Placement control experiments suggest that the drugs did
not spread beyond a distance of 1 mm around the tip of
the microdialysis probe, which is consistent with our pre-
vious estimates [35,37,38,70]. The distance between the
tips of the microdialysis probes in the CeLC (effective drug
administration site) and striatum (ineffective control site)
is about 2 mm. The striatum was selected as in our previ-
ous studies [43,45,46,48] because it is located adjacent
(dorsolateral) to the CeLC but does not project directly to
the CeLC [72]. Desensitization of CRF effects needs to be
considered. However, the persistence of CRF effects in the
presence of a CRF2 antagonist (Figure 1E) and PKC in-
hibitor (Figure 4E) and during prolonged drug application
(Figure 4C) argues against the loss of effectiveness, e.g.,
due to desensitization, as an explanation for the inhibitory
effect of the CRF1 antagonist and PKA inhibitor.
Conclusion
Non-pain-related activation of CRF1 receptors in the
amygdala can trigger pain-responses in normal animals
through a mechanism that involves PKA-dependent syn-
aptic facilitation in CeLC neurons independent of HPA
axis function. The study contributes novel insight into
CRF functions in the brain and into brain mechanisms
of pain. The results suggest that conditions of increased
amygdala CRF levels can trigger pain in the absence of
any tissue pathology or disease state.
Methods
Male Sprague Dawley rats (150–350 g) were housed in a
temperature controlled room and maintained on a 12 h
day/night cycle. Water and food were available ad libitum.
On the day of the experiment, rats were transferred from
the animal facility and allowed to acclimate to the labora-
tory for at least 1 h. All experimental procedures conform
to the guidelines of the International Association for the
Study of Pain (IASP) and of the National Institutes of
Health (NIH) and were approved by the Institutional
Animal Care and Use Committee (IACUC) at the Univer-
sity of Texas Medical Branch (UTMB).
Electrophysiology
Brain slice preparation
Coronal slices (300–500 μm) containing the CeLC were
obtained from normal untreated rats (150–230 g) as previ-
ously described [30,42,43] for recent references see [46].
Rats were decapitated without the use of anesthesia to
avoid chemical contamination of the tissue. A single brain
slice was transferred to the recording chamber and
submerged in artificial cerebrospinal fluid (ACSF; 31 ± 1°C),
which superfused the slice at ~2 ml/min. ACSF contained
(in mM) NaCl 117, KCl 4.7, NaH2PO4 1.2, CaCl2 2.5,MgCl2 1.2, NaHCO3 25, and glucose 11. The ACSF was
oxygenated and equilibrated to pH 7.4 with a mixture of
95% O2/5% CO2. Only one or two brain slices per animal
were used, one neuron was recorded in each slice, and a
fresh slice was used for each new experimental protocol.
Numbers in the manuscript refer to the number of neurons
tested for each parameter.
Patch-clamp recording
Whole-cell current- and voltage-clamp recordings were
made from CeLC neurons using the “blind” patch tech-
nique or DIC-IR video-microscopy as described before
for recent references see [30,42,43]. The boundaries of
the different amygdalar nuclei are easily discerned under
light microscopy see Figure 1 in [29]. Recording pipettes
(3–5 MΩ tip resistance) were made from borosilicate
glass (1.5 mm and 1.12 mm, outer and inner diameter, re-
spectively; Drummond, Broomall, PA) using a Flaming-
Brown micropipette puller (P-80/PC, Sutter Instrument
Co., Novato, CA). Electrodes were filled with intracellular
solution containing (in mM): 122 K-gluconate, 5 NaCl, 0.3
CaCl2, 2 MgCl2, 1 EGTA, 10 HEPES, 5 Na2-ATP, and 0.4
Na3-GTP; pH is adjusted to 7.2-7.3 with KOH and osmo-
larity to 280 mOsm/kg with sucrose. Data acquisition
and analysis was done using a dual 4-pole Bessel filter
(Warner Instr.), low-noise Digidata 1322 interface (Molecu-
lar Devices), Axoclamp-2B amplifier (Molecular Devices),
Pentium PC, and pClamp10 software (Molecular Devices).
Signals were low-pass filtered at 1 kHz and digitized at
5 kHz. Headstage voltage was monitored continuously on
an oscilloscope to ensure precise performance of the ampli-
fier. High GΩ seal and low series (<20 MΩ) resistances
were checked throughout the experiment (using pClamp10
membrane test function) to ensure high-quality recordings.
If series resistance (monitored with pClamp190 software)
changed more than 10%, the neuron was discarded.
Neurons were recorded at −60 mV except when NMDA
receptor-mediated responses were studied.
Synaptic transmission
Monosynaptic EPSCs were evoked in CeLC neurons by
focal electrical stimulation (Grass S88 stimulator) of inputs
from the PB. For stimulation of the PB-CeLC synapse, a
concentric bipolar stimulating electrode (SNE-100, Kopf
Instr.; 22 kW). was positioned under microscopic control
on the fiber tract that runs dorsomedial to the CeA and
ventral to but outside of the caudate-putamen [25,29]. In
the vicinity of this tract, no afferents to the CeA other than
from lateral PB have been described [19,20]. Electrical
stimuli (150 μs square-wave pulses) were delivered at
low frequencies (< 0.25 Hz). Input–output functions were
obtained by increasing the stimulus intensity in 100 μA
steps. For evaluation of a drug effect on synaptically
evoked responses, the stimulus intensity was adjusted to
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generation. EPSCs were recorded at −60 mV in the
presence of bicuculline (30 μM) except for the study of
NMDA receptor-mediated EPSCs, which were recorded
at +20 mV in the presence of bicuculline (30 μM) and
NBQX (20 μM) as in our previous studies [46].
Miniature EPSCs (mEPSCs, in TTX 1μM) were
measured as described previously [42,46]. A fixed length of
traces (5 min) was analyzed for frequency and amplitude
distributions using MiniAnalysis program 5.3 (Synaptosoft,
Decatur, GA). The root mean square (RMS) of the back-
ground noise was computed for each set of data. Detection
threshold for an event was set to 3–4 times the RMS value.
Peaks were detected automatically, but each detected event
was then visually inspected to prevent the inclusion of
false data.
Drug application
Drugs (see below, “Drugs”) were applied by gravity-driven
superfusion of the brain slice in the ACSF (~2 ml/min).
Solution flow into the recording chamber (1 ml volume)
was controlled with a three-way stopcock.
Behavioral tests
Adult male Sprague–Dawley rats (250–350 g) were used
in all experiments.
Spinal reflexes
Thresholds of hindlimb withdrawal reflexes evoked by
mechanical stimulation of the knee joint were measured
as described previously [47]. Mechanical stimuli of
continuously increasing intensity were applied to the
knee joint by means of a forceps equipped with a force
transducer, whose calibrated output was amplified and
displayed in grams on a liquid crystal display screen.
Withdrawal threshold was defined as the minimum
stimulus intensity that evoked a withdrawal reflex.
Vocalizations
Audible and ultrasonic vocalizations were recorded and
analyzed as described previously [43,70,73]. The experi-
mental setup (U.S. Patent 7,213,538) included a custom-
designed recording chamber, a condenser microphone
(audible range, 20 Hz to 16 kHz) connected to a pre-
amplifier, an ultrasound detector (set to record ultrasonic
vocalizations in the range of 25 ± 4 kHz), filter and amp-
lifier (UltraVox 4-channel system; Noldus Information
Technology). Vocalizations in the audible and ultrasonic
ranges were recorded simultaneously but with different
microphones (condenser microphone and bat detector,
respectively) connected to separate channels of the ampli-
fier. Data acquisition software (UltraVox 2.0; Noldus
Information Technology) monitored the occurrence of
vocalizations within user-defined frequencies and recordedthe number and duration of digitized events (audible
and ultrasonic vocalizations). The computerized recording
system was set to suppress non-relevant audible sounds
(background noise) and to ignore ultrasounds outside
the defined frequency range. Animals were placed in the
recording chamber for acclimation 1 h before the
vocalization measurements.
Brief (15 s) innocuous (500 g/30 mm2) and noxious
(2000 g/30 mm2) mechanical stimuli were applied to the
knee, using a calibrated forceps. Stimulus intensities of
100–500 g/30 mm2 applied to the knee and other deep
tissue are considered innocuous because they do not
evoke hindlimb withdrawal reflexes in awake rats and are
not felt to be painful when tested on the experimenters.
Pressure stimuli >1500 g/30 mm2 are noxious because
they evoke hindlimb withdrawal reflexes in awake rats and
are distinctly painful when applied to the experimenters
[47]. The total duration of vocalizations (arithmetic sum
of the duration of individual events) was recorded for
1 min, starting with the onset of the mechanical stimulus.
Drug application by microdialysis in awake animals
As described in detail previously [43,70], a guide cannula
was implanted stereotaxically the day before behavioral
measurements, using a stereotaxic apparatus (David Kopf
Instr.). The animal was anesthetized with pentobarbital
sodium (Nembutal, 50 mg/kg, i.p.) and a small unilateral
craniotomy was performed at the sutura frontoparietalis
level. The guide cannula was implanted on the dorsal
margin of the CeLC in the right hemisphere, where pain-
related changes have been shown [74], using the following
coordinates (in mm): CeLC, 2.0 caudal to bregma, 4.0
lateral to midline, depth 7.0. In some experiments a
guide cannula was implanted into the striatum as a place-
ment control, using the following stereotaxic coordinates:
2.0 mm caudal to bregma; 4.0 mm lateral to midline;
depth of tip 5.0 mm. The cannula was fixed to the skull
with dental acrylic (Plastics One). Antibiotic ointment was
applied to the exposed tissue to prevent infection.
On the day of the experiment, a microdialysis probe
(CMA12; CMA/Microdialysis Inc.; 20 kD cut-off, mem-
brane length 2 mm) was inserted through the guide can-
nula so that the probe protruded by 2 mm. The probe
was connected to an infusion pump (Harvard Apparatus)
and perfused with ACSF (oxygenated and equilibrated to
pH= 7.4). Drugs (see below, “Drugs”) were dissolved in
ACSF on the day of the experiment at a concentration
100-fold that predicted to be needed based on data from
our previous microdialysis and in vitro studies because
of the concentration gradient across the dialysis mem-
brane and diffusion in the tissue [29,35,37,70]. Numbers
in the manuscript refer to drug concentrations in the
microdialysis fiber. Drugs were applied by microdialysis
at a rate of 5 μl/min for at least 20 min to establish
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ACSF was pumped through the fiber for at least 1 h to
establish equilibrium in the tissue.
Histological verification of drug administration sites
The position of the microdialysis probe in the CeA or stri-
atum (placement control) was confirmed histologically. At
the end of each behavioral experiment, the animal was
euthanized by decapitation using a guillotine (Harvard
Apparatus Decapitator). The brain was removed and
submerged in 10% formalin. Tissues were stored in 20%
sucrose before they were frozen sectioned at 50 μm.
Sections were mounted on gel-coated slides, stained with
hematoxylin and eosin (H&E) and cover-slipped. Positions
of the microdialysis fibers were identified under the micro-
scope and plotted on standard diagrams adapted from
Paxinos and Watson [75].
Drugs
The following drugs were used: Corticotropin releasing fac-
tor (human, rat; CRF) was purchased from Bachem. 5-
chloro-4-(N-(cyclopropyl)methyl-N-propylamino)-2-methyl-
6-(2,4,6-trichlorophenyl) amino-pyridine (NBI 27914; CRF1
receptor antagonist) [66] was purchased from Tocris
Bioscience. Cyclo(31–34) [D-Phe11,His12,CαMeLeu13,39,
Nle17, Glu31, Lys34] Ac-Sauvagine(8–40) (astressin-2B;




acid, hexyl ester (KT5720; membrane-permeable potent and
selective PKA inhibitor) [76]; 2-[1-(3-dimethylaminopropyl)
indol-3-yl]-3-(indol-3-yl) maleimide (GF109203x; membrane-
permeable potent and selective PKC inhibitor) [77]; 2,3-
dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-
sulfonamide disodium salt (NBQX; non-NMDA receptor
antagonist); DL-2-amino-5-phosphonopentanoic acid (AP5;
NMDA receptor antagonist); [R-(R*,S*)]-6-(5,6,7,8-tetra-
hydro-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl)furo
[3,4-e]-1,3-benzodioxol-8(6H)-one (bicuculline; GABAA
receptor antagonist); and dexamethasone (to suppress
HPA axis function [51]) were purchased from Tocris
Bioscience. Selectivity and target concentrations have been
established in our previous studies [29,37,38,45]. Drugs
were dissolved in ACSF on the day of the experiment.
ACSF served as vehicle control in all experiments.
Statistical analysis
All averaged values are given as the mean ± SEM. Statis-
tical significance was accepted at the level P < 0.05.
GraphPad Prism 3.0 software (Graph-Pad Software,
San Diego, CA) was used for all statistical analysis. For
multiple comparisons, one-way or two-way ANOVA
was used with appropriate posttests as indicated. Pairedstudent t-test was used to compare two sets of data that fol-
low Gaussian distribution and have similar variances. Con-
centration–response curves were obtained by non-linear
regression analysis using the formula y =A + (B −A)/[1 +
(10C/10X)D], where A is the bottom plateau, B top plateau,
C = log(IC50), and D is the slope coefficient (GraphPad
Prism software). Kolmogorov-Smirnov test was used for
cumulative distribution analysis of mEPSCs (MiniAnalysis
program 5.3, Synaptosoft Inc.).
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